Company profile
Ticker
ABVX, AAVXF
Exchange
Employees
Incorporated
Fiscal year end
Industry (SIC)
SEC CIK
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
5 Apr 24
6-K
Abivax reports 2023 financial results and operational update
2 Apr 24
6-K
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
2 Feb 24
6-K
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
22 Jan 24
424B4
Prospectus supplement with pricing info
23 Oct 23
FWP
Free writing prospectus
20 Oct 23
EFFECT
Notice of effectiveness
20 Oct 23
EFFECT
Notice of effectiveness
20 Oct 23
SEC STAFF LETTER
SEC staff letter
20 Oct 23
CERT
Certification of approval for exchange listing
19 Oct 23
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Press releases
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
5 Apr 24
Abivax reports 2023 financial results and operational update
2 Apr 24
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)
13 Feb 24
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
7 Feb 24
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease
2 Feb 24